Oncotarget is respected for being one of the best scientific journals in the world. The special journal has been in the competitive market for a while now, and it has assisted very many individuals who are looking for information concerning cancer research and oncology. Although the journal has not been published for a long time, it has published several papers concerning age-related illnesses, endocrinology, phycology, pathology, and immunology.Oncotarget has done well in the competitive market for several reasons. First of all, the institution has very strict guidelines that ensure that the authors do not engage in activities that might alter the authenticity of the information published.The journal has done its best to avert any circumstances of falsification, plagiarism, fabrication, defamation and many other crimes related to publication.
These guidelines have made Oncotarget one of the most reliable journals in the medical field at the moment.Authors who are interested in working with the journal are always encouraged to describe their results in the most accurate and reliable manner so that the objective of their work can be understood by the audience. Before any information can be published in the journal, the management ensures that the detailed content has great references, so the reader is satisfied. Before an author can publish their research in the journal, the content must be reviewed by the editorial team who are led by Mikhail Blagosklonny.
Mikhail Blagosklonny has been in the medical profession for a very long time, and he is famed to be one of the most authoritative figures in Oncotarget.Under his leadership, the journal has published some of the complex topics, especially in cancer and aging. The respected scientist has a rich educational background, and he has a great understanding of what the consumer is looking for. The research papers published under his leadership have proven to be genuine with the right information. Before the research is published, Mikhail Blagosklonny and his professors take time to edit and check the information so that they can ascertain that it is correct. Some of the most popular publications specialize in aging and its relationship with cancer.
To promote precision medicine and accelerate research and development in the field of cancer research, a chair for Genome Science was recently established at Rutgers Cancer Institute. The chair was named after Omar Boraie, who is a serial entrepreneur and a legendary real estate developer based in New Brunswick. Omar Boraie has committed to making a donation of $1.5 Million reveals Bloomberg for the establishment of the Omar Boraie Chair, which is challenge initiative of the Rutgers University and a part of 18 Chair Challenge campaign. An anonymous donor has pledged to provide donation matching $1.5 Million for each chair, which raises the total endowment for each chair to $3 Million.
The world of medical science and cancer research has rapidly advanced in the last few years, and one of the branches that have shown some positive results is precision medicine and genome science. It helps the physicians and scientists to study the case of each patient on a genetic level, which helps in individualizing the treatment offered. The gene sequencing is done and practiced at many cancer centers across the globe, but Rutgers Cancer Institute was the first establishment in the country to collaborate genomic sequencing and the practice of precision medicine to offer an efficient treatment to the patients. In his state of Union Address, former U.S. President Obama announced last year how precision medicine could help in advancing cancer research initiatives. He also announced the launch of Precision Medicine program that would focus on finding a cure for cancer and better cancer therapies.
Sam Boraie for many decades has been a part of the development and success story of New Brunswick, and supporting this chair through his pledge is just another step towards helping the community on a broader scale. He has a background in chemistry and has for long been interested in the initiative for cancer research. He believes that the donation of his family and others in the 18 Chair would also help other affluent members of the society to come forward to support the cause. A news piece on the Omar Boraie’s contribution towards the formation of Chair is also published on NewsWise, a leading online news publication.
The chair has been assigned to the well-known Oncologist, Shridar Ganesan, MD, and Ph.D., who before joining Rutgers Cancer Institute was working with Dana-Farber Cancer Institute, which is a cancer research arm of Harvard Medical School. The formation of the chair would encourage the physicians and scientists working in the field of clinical research in precision medicine and cancer therapies.